Immuron Ltd ADR

Immuron Ltd ADR FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Immuron Ltd ADR (IMRN) as of Nov 3, 2026 is 79.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 117.66 % — a change of -32.03% (lower).

FCF Conversion

79.98 %

YoY

-32.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Immuron Ltd ADR is 2026 79.98 % . FCF Conversion Rate (FCF/EBITDA) of Immuron Ltd ADR was 2025 117.66 % . It decreases by -32.03% lower compared to the previous year.

The Immuron Ltd ADR FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
27.65 USD
Jan 1, 2020
108.98 USD
Jan 1, 2021
36.39 USD
Jan 1, 2022
110.09 USD
Jan 1, 2023
65.93 USD
Jan 1, 2024
84.77 USD
Jan 1, 2025
117.66 USD
Jan 1, 2026
79.98 USD
The Immuron Ltd ADR FCF Conversion history
YEARFCF ConversionYoY
79.98 %-32.03%
117.66 %+38.80%
84.77 %+28.58%
65.93 %-40.12%
110.09 %+202.55%
36.39 %-66.61%
108.98 %+294.08%
27.65 %-76.29%
116.61 %+12.76%
103.42 %+94.66%
53.13 %-52.71%
112.34 %+13.41%
99.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Immuron Ltd ADR Stock analysis

What does Immuron Ltd ADR do? Immuron Ltd ADR is a biopharmaceutical company listed on the US market in 2017, operating from Carlton. The firm engages in the research, development, and commercialization of polyclonal antibodies across Australia, the United States, and Canada. It operates through Research and Development and Hyper-immune Products segments. Immuron offers Travelan, an over-the-counter medicine and dietary supplement for digestive health, and Protectyn, an immune supplement. The company also develops clinical-stage candidates, including Travelan (IMM-124E) and IMM-529 for gastrointestinal conditions, alongside the pre-clinical IMM-986. Additionally, Immuron provides a technology platform and maintains collaborations for therapeutic development. Immuron Ltd ADR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immuron Ltd ADR stock

FCF Conversion Rate (FCF/EBITDA) of Immuron Ltd ADR is 79.98 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Immuron Ltd ADR changed from 117.66 % to 79.98 %, representing a -32.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Immuron Ltd ADR since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Immuron Ltd ADR with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Immuron Ltd ADR

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Immuron Ltd ADR